Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001999973 | SCV002228994 | pathogenic | Combined immunodeficiency with skin granulomas; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive | 2023-11-24 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys287Alafs*6) in the RAG2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 241 amino acid(s) of the RAG2 protein. This variant is present in population databases (rs754975137, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with severe combined immunodeficiency/ Omenn syndrome (PMID: 24144642; Invitae). ClinVar contains an entry for this variant (Variation ID: 1452768). This variant disrupts the p.Trp453 amino acid residue in RAG2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10891502, 12200379, 20234091). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV004571712 | SCV005054064 | pathogenic | Combined immunodeficiency with skin granulomas | 2024-03-07 | criteria provided, single submitter | clinical testing |